BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gerich ME, Yoon JL, Targan SR, Ippoliti AF, Vasiliauskas EA. Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther 2015;41:429-37. [PMID: 25511905 DOI: 10.1111/apt.13057] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Manuc TE, Manuc MM, Diculescu MM. Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets. Clin Exp Gastroenterol 2016;9:59-70. [PMID: 27042137 DOI: 10.2147/CEG.S53381] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
3 Zhu Z, Li M, Shu X, Bai A, Long S, Liu D, Lu N, Zhu X, Liao W. Thalidomide is a therapeutic agent that is effective in inducing and maintaining endoscopic remission in adult CD patients. Clinics and Research in Hepatology and Gastroenterology 2017;41:210-6. [DOI: 10.1016/j.clinre.2016.09.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
4 Grossi V, Hyams JS. The safety of treatment options for pediatric Crohn’s disease. Expert Opinion on Drug Safety 2016;15:1383-90. [DOI: 10.1080/14740338.2016.1203418] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Feng R, Xu PP, Chen BL, Mao R, Zhang SH, Qiu Y, Zeng ZR, Chen MH, He Y. CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide in the treatment of immune-related bowel disease. J Dig Dis 2020;21:98-103. [PMID: 31916702 DOI: 10.1111/1751-2980.12842] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Simon M, Pariente B, Lambert J, Cosnes J, Bouhnik Y, Marteau P, Allez M, Colombel JF, Gornet JM. Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease. Clin Gastroenterol Hepatol 2016;14:966-972.e2. [PMID: 26598226 DOI: 10.1016/j.cgh.2015.10.034] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
7 García-cabo C, Morís G. Peripheral neuropathy: An underreported neurologic manifestation of inflammatory bowel disease. European Journal of Internal Medicine 2015;26:468-75. [DOI: 10.1016/j.ejim.2015.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
8 Liu M, Lin X, Wang L, He Y, Chen M, Mao R. Thalidomide-induced sinus bradycardia in Crohn's disease: case report and literature review. J Int Med Res 2019;47:2228-33. [PMID: 30832535 DOI: 10.1177/0300060519833293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
9 Bramuzzo M, Stocco G, Montico M, Arrigo S, Calvi A, Lanteri P, Costa S, Pellegrino S, Magazzù G, Barp J, Ghione S, Lionetti P, Zuin G, Fontana M, Di Chio T, Maggiore G, Lazzerini M, Lucafò M, Udina C, Pellegrin MC, Chicco A, Carrozzi M, Decorti G, Ventura A, Martelossi S. Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis 2017;23:1810-6. [PMID: 28817461 DOI: 10.1097/MIB.0000000000001195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bramuzzo M, Ventura A, Martelossi S, Lazzerini M. Thalidomide for inflammatory bowel disease: Systematic review. Medicine (Baltimore) 2016;95:e4239. [PMID: 27472695 DOI: 10.1097/MD.0000000000004239] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 5.6] [Reference Citation Analysis]
11 Issa NT, Kruger J, Wathieu H, Raja R, Byers SW, Dakshanamurthy S. DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing. BMC Bioinformatics 2016;17:202. [PMID: 27151405 DOI: 10.1186/s12859-016-1065-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hu H, Wang X, Liu S. Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review. Medicine (Baltimore) 2016;95:e4799. [PMID: 27603389 DOI: 10.1097/MD.0000000000004799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
13 He Y, Mao R, Chen F, Xu PP, Chen BL, Wu Y, Qiu Y, Zhang SH, Feng R, Zeng ZR, Ben-Horin S, Chen MH. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. Therap Adv Gastroenterol 2017;10:397-406. [PMID: 28507598 DOI: 10.1177/1756283X17698910] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
14 Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol 2015;8:257-69. [PMID: 26316792 DOI: 10.2147/CEG.S58152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
15 Rogler G. Editorial: is thalidomide a good option for patients with refractory Crohn's disease? Aliment Pharmacol Ther 2015;41:785-6. [PMID: 25781038 DOI: 10.1111/apt.13106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Jiang F, Peng X, Cai D, Wen D, Liu Y, Zhi M, Chen J, Hu P, Wang X, Gao Y, Huang M, Gao X, Zhong G. A validated LC-MS/MS method for the simultaneous determination of thalidomide and its two metabolites in human plasma: Application to a pharmacokinetic assay. Biomed Chromatogr 2018;32:e4240. [PMID: 29529709 DOI: 10.1002/bmc.4240] [Reference Citation Analysis]